Drugs Made In America Acquisition Corp. (DMAA) stock
DMAANasdaqBlank ChecksFiscal year ends December 31Also trades as DMAAR, DMAAU
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$10.90+0.00 (0.00%)
Close on Nov 16, 2026Market cap $264.62MP/E –Yield –
Drugs Made In America Acquisition total assets
Total assets on the balance sheet at the end of each period.
Drugs Made In America Acquisition's total assets was $146.90M at Jun 30, 2026. For fiscal 2025 it was $239.92M, up 43456.4% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $239.92M | +43456.4% |
| FY2024 | Dec 31, 2024 | $550.82K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $146.90M | -37.5% |
| Q1 FY2026 | Mar 31, 2026 | $242.04M | +4.0% |
| Q4 FY2025 | Dec 31, 2025 | $239.92M | +43456.4% |
| Q3 FY2025 | Sep 30, 2025 | $237.63M | – |
| Q2 FY2025 | Jun 30, 2025 | $235.21M | – |
| Q1 FY2025 | Mar 31, 2025 | $232.81M | – |
| Q4 FY2024 | Dec 31, 2024 | $550.82K | – |
See a number that looks wrong?